Can Kelun-Biotech and Merck turn sac-TMT into the first ADC plus immunotherapy standard in front-line lung cancer?

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) has moved its TROP2-directed antibody drug conjugate sacituzumab tirumotecan deeper into global oncology visibility after Phase III OptiTROP-Lung05 results were published in The Lancet and presented at the 2026 American Society of Clinical Oncology Annual Meeting. The study evaluated sacituzumab tirumotecan in combination with Merck & Co., Inc.’s (NYSE: MRK) pembrolizumab as first-line treatment for PD-L1-positive advanced non-small cell lung cancer. The data matter because the combination reduced the risk of disease progression or death versus pembrolizumab alone, while also showing a positive overall survival trend. For investors, the readout sharpens the strategic importance of Merck & Co., Inc.’s 2022 ex-Greater China licensing deal with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. at a time when Merck & Co., Inc. is under pressure to extend its oncology growth story beyond pembrolizumab.

Why does The Lancet publication matter for sacituzumab tirumotecan in PD-L1-positive non-small cell lung cancer?

The Lancet publication gives OptiTROP-Lung05 a higher level of clinical visibility than a conference abstract alone, which is important because sacituzumab tirumotecan is no longer just a China-origin oncology asset with promising regional data. It is becoming a test case for whether antibody drug conjugates can move from later-line oncology settings into the first-line treatment architecture of advanced non-small cell lung cancer, where immunotherapy has already reshaped standard care.

OptiTROP-Lung05 was designed as a randomized, open-label, multicenter Phase III trial comparing sacituzumab tirumotecan plus pembrolizumab against pembrolizumab monotherapy in patients with locally advanced or metastatic non-small cell lung cancer whose tumors had PD-L1 tumor proportion scores of at least 1%. That patient population is strategically meaningful because pembrolizumab monotherapy is already a major benchmark in PD-L1-positive disease, making the trial a direct challenge to an established immuno-oncology standard rather than a marginal experiment in a niche setting.

The reported hazard ratio of 0.35 for progression-free survival suggests a substantial reduction in the risk of disease progression or death. The company also reported progression-free survival benefits across PD-L1 expression and histology subgroups, including patients with PD-L1 tumor proportion scores of at least 50%, patients with scores of 1% to 49%, non-squamous disease, and squamous disease. That breadth matters because lung cancer markets are not won by one clean headline number. They are won by whether clinicians see enough consistency across real-world patient segments to justify changing treatment habits.

How could sacituzumab tirumotecan change Merck & Co., Inc.’s Keytruda growth strategy?

For Merck & Co., Inc., the central strategic issue is not whether pembrolizumab remains a dominant oncology product today. It clearly does. The issue is how Merck & Co., Inc. protects and extends the pembrolizumab franchise as competitive intensity rises and investors keep asking what comes after the immuno-oncology mega-cycle.

Sacituzumab tirumotecan gives Merck & Co., Inc. a credible answer in one of the most commercially important cancer categories. Instead of replacing pembrolizumab, the strategy is to pair pembrolizumab with targeted payload delivery through a TROP2-directed antibody drug conjugate. That allows Merck & Co., Inc. to reposition immunotherapy from a standalone backbone into a combination platform, which is exactly where large oncology companies prefer to play when standard-of-care markets mature.

The logic is simple but powerful. Pembrolizumab helps activate immune response, while sacituzumab tirumotecan is designed to deliver a cytotoxic payload into TROP2-expressing tumor cells. If that combination produces durable clinical benefit without an unacceptable safety penalty, Merck & Co., Inc. could defend share in front-line non-small cell lung cancer while also building a broader antibody drug conjugate franchise across tumor types. In pharma terms, that is not just pipeline diversification. It is franchise architecture.

The risk is equally clear. Combination regimens must justify added toxicity, added cost, and added complexity. Pembrolizumab monotherapy is attractive partly because it is familiar, widely adopted, and commercially entrenched. To displace or modify that treatment pattern, sacituzumab tirumotecan must continue to show that the magnitude of benefit is strong enough to outweigh the friction. Oncology may love novelty, but payers and clinicians still check the bill.

Why is the ADC plus immunotherapy model becoming more important in first-line oncology?

The OptiTROP-Lung05 result lands in a broader industry shift in which antibody drug conjugates are moving from salvage therapy into earlier lines of treatment. That transition is commercially important because earlier-line use usually means larger patient pools, longer treatment duration, and higher strategic value. It also raises the evidentiary bar, because first-line regimens must compete against better-established options in patients who may still have multiple therapeutic pathways available.

The phrase ADC plus immunotherapy sounds like neat biotech algebra, but the business implications are more complex. If the model works in lung cancer, it could encourage more companies to test antibody drug conjugates not just as chemotherapy replacements, but as immune sensitizers or partners to checkpoint inhibitors. That would intensify competition among TROP2 assets and other tumor-associated antigen platforms, including programs from major oncology players already fighting for position in breast cancer, lung cancer, urothelial cancer, and gastrointestinal cancers.

For Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., the result strengthens the company’s position as one of China’s most visible antibody drug conjugate innovators. The company has already secured approvals for sacituzumab tirumotecan in China across multiple indications, and the new lung cancer data make the asset harder for global investors to dismiss as a regionally contained molecule. That is the fun bit, if one can call oncology dealmaking fun without upsetting the compliance department.

What does the China regulatory pathway signal for sacituzumab tirumotecan’s commercial potential?

The China regulatory pathway is already becoming a key part of the story. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. previously announced that a supplemental new drug application for sacituzumab tirumotecan in combination with pembrolizumab had been accepted for review by China’s National Medical Products Administration for adult patients with locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score of at least 1%, and without EGFR or ALK alterations.

That detail is commercially important because it positions sacituzumab tirumotecan for a potentially broader first-line lung cancer indication in China, where local regulatory decisions can also influence global perception of Chinese-origin oncology assets. If approval follows, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. would gain another marketed use for sacituzumab tirumotecan in a high-incidence cancer category, while Merck & Co., Inc. would benefit from stronger validation for ex-Greater China development.

China is no longer just a low-cost clinical trial jurisdiction in oncology. It is becoming a competitive proving ground where domestic innovators generate pivotal data, secure local approvals, and then use global partners to test whether those assets can travel. Sacituzumab tirumotecan fits that model neatly. The molecule was discovered by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., while Merck & Co., Inc. controls rights outside Greater China through its 2022 licensing arrangement.

The biggest uncertainty is whether Chinese Phase III data will translate cleanly into regulatory and commercial success in the United States, Europe, and other major markets. Regulators may want additional global data, clinicians may want more mature overall survival evidence, and payers may want proof that a more intensive regimen delivers value beyond progression-free survival. The first-line oncology market does not hand out permanent seats at the table. It rents them, expensively.

How should investors read the latest Merck & Co., Inc. and Kelun-Biotech stock sentiment?

Merck & Co., Inc. shares recently traded at $118.72, with the stock sitting below its 52-week high of $125.14 but well above its 52-week low of $75.40. The stock has shown mixed near-term momentum, with a reported five-day performance decline but a stronger one-month gain. That tells investors something useful: the market is willing to reward oncology pipeline validation, but Merck & Co., Inc. is still being judged through the larger lens of post-pembrolizumab durability, patent exposure, and late-stage pipeline conversion.

The sacituzumab tirumotecan data are therefore sentiment-positive, but not yet thesis-completing. For Merck & Co., Inc., investors will want to see whether the asset can support approvals outside Greater China, whether global Phase III programs can reproduce or extend the China signal, and whether safety data remain manageable when exposed to broader clinical use. A single strong trial can move sentiment. A label-changing global program can move valuation.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. offers a more direct but higher-beta exposure to sacituzumab tirumotecan. Recent market data show the Hong Kong-listed stock trading around HK$462, with a 52-week range of HK$309.20 to HK$581.00 and a market capitalization above HK$100 billion. That valuation already reflects significant confidence in the company’s antibody drug conjugate platform, which means future upside may depend less on whether sacituzumab tirumotecan is interesting and more on whether the company can convert clinical momentum into approvals, reimbursement, and milestone economics.

The investor read-through is cautiously constructive. Merck & Co., Inc. gets a potentially important extension tool for its oncology empire. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. gets global credibility and a stronger bargaining position as China’s biotech sector continues to produce exportable assets. The caveat is that antibody drug conjugates are becoming crowded, and crowded markets are rarely kind to second-best data.

What execution risks could limit the commercial impact of sacituzumab tirumotecan?

The first risk is survival maturity. Progression-free survival is clinically meaningful, especially when the hazard ratio is strong, but first-line lung cancer markets ultimately place heavy weight on overall survival, duration of response, tolerability, quality of life, and subgroup consistency. The reported overall survival trend is encouraging, but investors and clinicians will look for more mature results before treating the regimen as a durable strategic shift.

The second risk is safety management. Antibody drug conjugates can carry hematologic, gastrointestinal, and payload-related toxicities, while pembrolizumab brings immune-mediated safety considerations. Even when no new safety signal is identified, combination therapy can increase monitoring complexity. In real-world oncology practice, a regimen must fit into clinic workflows, not just statistical tables.

The third risk is competitive timing. The TROP2 antibody drug conjugate field is one of the busiest lanes in oncology, with large pharmaceutical companies and specialist biotechs pursuing overlapping tumor types. If rival assets show cleaner safety, stronger survival, or easier dosing, sacituzumab tirumotecan’s advantage could narrow. The window is open, but it will not stay open politely.

Key takeaways on what sacituzumab tirumotecan means for Merck & Co., Inc., Kelun-Biotech and lung cancer treatment

• Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has strengthened sacituzumab tirumotecan’s credibility by securing both The Lancet publication and ASCO 2026 oral presentation visibility for OptiTROP-Lung05.
• The Phase III trial result is strategically significant because it tests an antibody drug conjugate plus immunotherapy combination against pembrolizumab alone in first-line PD-L1-positive advanced non-small cell lung cancer.
• Merck & Co., Inc. gains a potential pathway to extend the pembrolizumab franchise by pairing its immunotherapy backbone with targeted cytotoxic delivery rather than relying only on checkpoint inhibition.
• The reported progression-free survival hazard ratio of 0.35 gives the regimen a strong efficacy signal, while subgroup consistency improves the likelihood that clinicians will view the data as broadly relevant.
• The positive overall survival trend is important but still needs maturity, because front-line non-small cell lung cancer treatment decisions often depend on durable survival and tolerability evidence.
• China’s National Medical Products Administration review pathway could make China the first major commercial proving ground for the sacituzumab tirumotecan and pembrolizumab combination in this indication.
• Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is becoming a more visible global antibody drug conjugate player, helped by its 2022 ex-Greater China licensing partnership with Merck & Co., Inc.
• The main commercial risks are safety burden, reimbursement scrutiny, global regulatory transferability, and rising competition across the TROP2 antibody drug conjugate landscape.
• For investors, Merck & Co., Inc. offers lower-risk exposure to the asset within a diversified oncology franchise, while Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. offers more direct but more volatile exposure.
• The broader industry signal is clear: antibody drug conjugates are pushing into first-line oncology, and the next competitive battleground may be combination regimens rather than single-agent novelty.